Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

被引：14

作者：

Luo, Shuang ^{[1
,2
,3
,4
]}

Jiang, Yu ^{[5
]}

Zheng, Anfu ^{[1
,2
,3
]}

Zhao, Yueshui ^{[1
,2
,3
]}

Wu, Xu ^{[1
,2
,3
]}

Li, Mingxing ^{[1
,2
,3
]}

Du, Fukuan ^{[1
,2
,3
]}

Chen, Yu ^{[1
,2
,3
]}

Deng, Shuai ^{[1
,2
,3
]}

Chen, Meijuan ^{[1
,2
,3
]}

Li, Wanping ^{[1
,2
,3
]}

Li, Xiaobing ^{[1
,2
,3
]}

Gu, Li ^{[1
,2
,3
]}

Sun, Yuhong ^{[1
,2
,3
]}

Xiao, Zhangang ^{[2
,6
]}

Shen, Jing ^{[1
,2
,3
]}

机构：

[1] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China

[2] Cell Therapy & Cell Drugs Luzhou Key Lab, Luzhou, Peoples R China

[3] South Sichuan Inst Translat Med, Luzhou, Peoples R China

[4] Second Peoples Hosp Jiangyou, Dept Pharm, Mianyang, Peoples R China

[5] Peoples Hosp Wusheng, Dept Pharm, Guangan, Peoples R China

[6] Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

hypoxia-inducible factors; breast cancer; drug delivery systems; tumor microenvironment; angiogenesis; glycolysis; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELL; TUMOR ANGIOGENESIS; FACTOR-I; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA HIF-1-ALPHA; ANTIANGIOGENIC THERAPY; ANTICANCER ACTIVITY; AEROBIC GLYCOLYSIS; MASTER REGULATORS; PYRUVATE-KINASE;

D O I：

10.3389/fphar.2022.1064661

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hypoxia-inducible factors (HIFs), central regulators for cells to adapt to low cellular oxygen levels, are often overexpressed and activated in breast cancer. HIFs modulate the primary transcriptional response of downstream pathways and target genes in response to hypoxia, including glycolysis, angiogenesis and metastasis. They can promote the development of breast cancer and are associated with poor prognosis of breast cancer patients by regulating cancer processes closely related to tumor invasion, metastasis and drug resistance. Thus, specific targeting of HIFs may improve the efficiency of cancer therapy. In this review, we summarize the advances in HIF-related molecular mechanisms and clinical and preclinical studies of drugs targeting HIFs in breast cancer. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for HIF targeting are increasingly being developed. Therefore, we highlight the HIF related DDS, including liposomes, polymers, metal-based or carbon-based nanoparticles.

引用

页数：20

共 50 条

[1] Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy
Rey, Sergio
Schito, Luana
Wouters, Bradly G.
Eliasof, Scott
Kerbel, Robert S.
TRENDS IN CANCER, 2017, 3 (07): : 529 - 541
[2] Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, Caroline
Pahlman, Sven
Bexell, Daniel
PHARMACOLOGY & THERAPEUTICS, 2016, 164 : 152 - 169
[3] Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer
Din, Saba Musleh Ud
Streit, Spencer G.
Huynh, Bao Tran
Hana, Caroline
Abraham, Anna-Ninny
Hussein, Atif
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
[4] Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, Gregg L.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59, 2019, 59 : 379 - 403
[5] Role of hypoxia-inducible factors in breast cancer metastasis
Gilkes, Daniele M.
Semenza, Gregg L.
FUTURE ONCOLOGY, 2013, 9 (11) : 1623 - 1636
[6] Hypoxia-inducible factors and cancer
M. J. Calzada
L. del Peso
Clinical and Translational Oncology, 2007, 9 : 278 - 289
[7] Hypoxia-Inducible Factors and Cancer
Jun J.C.
Rathore A.
Younas H.
Gilkes D.
Polotsky V.Y.
Current Sleep Medicine Reports, 2017, 3 (1) : 1 - 10
[8] Hypoxia-Inducible Factors in Cancer
Kim, Laura C.
Simon, M. Celeste
CANCER RESEARCH, 2022, 82 (02) : 195 - 196
[9] Hypoxia-inducible factors and cancer
Calzada, M. J.
del Peso, L.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (05): : 278 - 289
[10] Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Li, Y.
Ye, D.
CURRENT CANCER DRUG TARGETS, 2010, 10 (07) : 782 - 796

← 1 2 3 4 5 →